The SphReI-HxVaccine Trial features many first-of-its-kind features

Learn more about the clinical trial at

https://hxvaccine.org 

Highlights:

• Unique open-adaptable design
• Researchers can load their trials related to aspects of COVID-19 and benefit from distributed grid-based data capture and advanced heuristic analyses.
• Funded with an 8tn  U allocation backed by €8tn in Q8 Treasury asset pledges.
• Participating countries can benefit from €10bn to €1tn in infrastructure investment through UNIPAC interfaces with their central banks.
• Transparency and regulatory compliance makes it efficient for hospitals and clinicians to participate.